Retinal Physician

The July/August career, education, and practice management issue is live now! https://www.retinalphysician.com/issu/2021/july-august-2021

Did you miss the most recent issue of New Retinal Physician? Flip through the pages here:

GIVEAWAY ALERT! In honor of #SocialMediaDay, we at Retinal Physician want to thank you for being part of our community! Today-and every day-we’re excited to deliver information + inspiration to your social media feed. Leave a comment right here letting us know what type of content you value the most by 11:59pm ET tonight (6/30) for a chance to win a $100 American Express gift card! https://buff.ly/3jjacnC

Flip through the pages of the latest issue: #retinaldisease #antivegf #drugdelivery

Protocol AB began its multicenter randomized clinical trial in 2016 to compare 2 mg aflibercept (Eylea; Regeneron) to PPV in type-1 and type-2 diabetic eyes with vitreous hemorrhages. What have we learned from the study?

To assess visual acuity outcomes and anti-VEGF therapy intensity in RVO-related macular edema ME, a retrospective study was completed in 15,613 eyes of treatment-naïve patients. Scroll to "Anti-VEGF Highly Effective Against RVO-Related ME."

Researchers from the University of Alberta have developed a new set of quantitative criteria to differentiate central serous chorioretinopathy from wet AMD. Scroll to "Distinguishing Central Serous Chorioretinopathy From Wet AMD" for more:

Aura Biosciences said its light-activated intravitreal therapy for ocular melanoma has been shown to preserve an average of 91% of vision. Scroll to "Aura Biosciences Therapy Preserves Vision in Ocular Melanoma." https://buff.ly/39kdRLj

Interim data from the phase 1 study of the OTX-TKI axitinib intravitreal implant for wet AMD continues to demonstrate that it has been generally well tolerated with a favorable safety profile. Scroll to "Ocular Therapeutix AMD Implant Effective in Phase 1."

Suprachoroidal Drug Delivery Scores Well in Study: Physician users report the administration technique to be applicable to a range of anatomic and demographic variables.

Michael Singer, MD, interviews Christina Weng, MD, about #diabeticretinopathy and its management in terms of #patientcompliance.

Wet AMD Patients Prefer PDS Implant Over Injections: Patients underwent only 2 procedures in 40 weeks.

Gemini Geographic Atrophy Drug to Advance Into Phase 2 Trial: Recombinant form of complement factor H met phase 1 endpoints.

In the COVID-19 (and post-COVID-19) era, there’s a need for all practices to review and enhance management strategies that prepare for unexpected events. Read more in the Practice Management Insider: https://buff.ly/2M5fnJl #practicemanagement #retinapractice

OpRegen Cell Therapy Has Positive Data in Geographic Atrophy: Visual acuity gains were maintained up to 24 months.